CO2018012857A2 - Composiciones antineoplásicas - Google Patents

Composiciones antineoplásicas

Info

Publication number
CO2018012857A2
CO2018012857A2 CONC2018/0012857A CO2018012857A CO2018012857A2 CO 2018012857 A2 CO2018012857 A2 CO 2018012857A2 CO 2018012857 A CO2018012857 A CO 2018012857A CO 2018012857 A2 CO2018012857 A2 CO 2018012857A2
Authority
CO
Colombia
Prior art keywords
prostate cancer
castration
resistant
rna
abiraterone acetate
Prior art date
Application number
CONC2018/0012857A
Other languages
English (en)
Spanish (es)
Inventor
Johny Bertels
Jurgen Mensch
Original Assignee
Aragon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56148120&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2018012857(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aragon Pharmaceuticals Inc filed Critical Aragon Pharmaceuticals Inc
Publication of CO2018012857A2 publication Critical patent/CO2018012857A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CONC2018/0012857A 2016-06-03 2018-11-27 Composiciones antineoplásicas CO2018012857A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16172968 2016-06-03
PCT/US2017/032815 WO2017209939A1 (en) 2016-06-03 2017-05-16 Anticancer compositions

Publications (1)

Publication Number Publication Date
CO2018012857A2 true CO2018012857A2 (es) 2018-12-14

Family

ID=56148120

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0012857A CO2018012857A2 (es) 2016-06-03 2018-11-27 Composiciones antineoplásicas

Country Status (24)

Country Link
US (1) US20190216829A1 (https=)
EP (1) EP3463377A1 (https=)
JP (1) JP2019517497A (https=)
KR (1) KR20190015314A (https=)
CN (1) CN109219437A (https=)
AR (1) AR108489A1 (https=)
AU (1) AU2017275396A1 (https=)
BR (1) BR112018074965A2 (https=)
CA (1) CA3024872A1 (https=)
CL (1) CL2018003403A1 (https=)
CO (1) CO2018012857A2 (https=)
CR (1) CR20180600A (https=)
EA (1) EA201892828A1 (https=)
IL (1) IL263157A (https=)
MA (1) MA45090A (https=)
MX (1) MX2018014846A (https=)
NI (1) NI201800127A (https=)
PE (1) PE20181925A1 (https=)
PH (1) PH12018502334A1 (https=)
SG (1) SG11201809680QA (https=)
TN (1) TN2018000366A1 (https=)
TW (1) TW201808287A (https=)
UA (1) UA124154C2 (https=)
WO (1) WO2017209939A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3019912T3 (en) * 2014-12-05 2025-05-21 Aragon Pharmaceuticals Inc Anticancer compositions
WO2016090098A1 (en) 2014-12-05 2016-06-09 Aragon Pharmaceuticals, Inc. Anticancer compositions
CZ2016573A3 (cs) 2016-09-16 2018-03-28 Zentiva, K.S. Pevná formulace abirateronu acetátu vyráběná technologií fluidní granulace
CN109125276A (zh) * 2017-06-19 2019-01-04 齐鲁制药有限公司 一种醋酸阿比特龙片剂的药物组合物及其制备方法
WO2019155416A2 (en) * 2018-02-09 2019-08-15 Kashiv Pharma Llc A stable pharmaceutical composition of poorly soluble nonsteroidal antiandrogens
US11865215B2 (en) 2018-04-26 2024-01-09 Synthon B.V. Tablet compositions comprising abiraterone acetate
EP3999040A4 (en) 2019-07-15 2023-07-19 Shilpa Medicare Limited DISPERSABLE TABLETS OF ABIRATERONACETATE
JP2022091129A (ja) * 2020-12-08 2022-06-20 東和薬品株式会社 組成物ならびにその製造方法および用途
WO2025174375A1 (en) * 2024-02-15 2025-08-21 Aragon Pharmaceuticals, Inc. Anticancer compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2265624B (en) 1992-03-31 1995-04-19 British Tech Group 17-substituted steroids useful in cancer treatment
EA201992010A1 (ru) 2012-06-07 2020-01-24 Арагон Фармасьютикалз, Инк. Кристаллическая форма а 4-[7-(6-циано-5-трифторметилпиридин-3-ил)-8-оксо-6-тиоксо-5,7-диазаспиро[3.4]окт-5-ил]-2-фтор-n-метилбензамида для лечения заболевания или состояния, связанного с активностью андрогенных рецепторов, включая рак простаты
MX2015013247A (es) * 2013-03-15 2016-11-25 Iceutica Inc Formulacion de acetato de abiraterona.
CA2940984A1 (en) * 2014-02-05 2015-08-13 Lek Pharmaceuticals D.D. Solid pharmaceutical compositions of androgen receptor antagonists
TWI831347B (zh) * 2014-08-08 2024-02-01 日商中外製藥股份有限公司 包含４環性化合物的非晶質體之固體分散體及製劑

Also Published As

Publication number Publication date
AU2017275396A1 (en) 2018-11-22
CR20180600A (es) 2019-07-11
PE20181925A1 (es) 2018-12-11
SG11201809680QA (en) 2018-11-29
CN109219437A (zh) 2019-01-15
EP3463377A1 (en) 2019-04-10
BR112018074965A2 (pt) 2019-03-12
IL263157A (en) 2018-12-31
PH12018502334A1 (en) 2019-07-29
TN2018000366A1 (en) 2020-06-15
CL2018003403A1 (es) 2019-02-01
US20190216829A1 (en) 2019-07-18
KR20190015314A (ko) 2019-02-13
UA124154C2 (uk) 2021-07-28
JP2019517497A (ja) 2019-06-24
WO2017209939A1 (en) 2017-12-07
MX2018014846A (es) 2019-03-14
CA3024872A1 (en) 2017-12-07
TW201808287A (zh) 2018-03-16
EA201892828A1 (ru) 2019-05-31
NI201800127A (es) 2019-03-29
AR108489A1 (es) 2018-08-29
MA45090A (fr) 2021-04-28

Similar Documents

Publication Publication Date Title
CO2018012857A2 (es) Composiciones antineoplásicas
MX2017007203A (es) Composiciones anticancerigenas.
MX2017007201A (es) Composiciones anticancerigenas.
Chen et al. PI 3K/Akt/mTOR pathway dual inhibitor BEZ 235 suppresses the stemness of colon cancer stem cells
PH12017500979A1 (en) Anticancer compositions
WO2017218844A3 (en) Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
WO2016196776A3 (en) Inhibitors of bruton's tyrosine kinase
EP3356522A4 (en) COMPOSITIONS WITH PROTEIN-LOADED EXOSOME AND METHOD FOR THE PREPARATION AND RELEASE THEREOF
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
MX375752B (es) Inhibidores de tirosina quinasa de bruton.
BR212016030926U2 (pt) conjugados de alvo e partículas e formulações dos mesmos
TR201818814T4 (tr) Dll4 antagonist antikorlarının ve anti-hipertansif ajanların terapötik kombinasyonu ve kullanımı.
MX2020004960A (es) Asociacion de activos para tratar el cancer de prostata.
MX2020007559A (es) Formulaciones farmaceuticas.
HK1219896A1 (zh) 使用4-氨基-2-(2，6-二氧代-呱啶-3-基)-异吲哚啉-1，3-二酮治疗和控制中枢神经系统癌症的方法和组合物
Kang et al. Breakthroughs in immune checkpoint therapy: overcoming NSCLC immune checkpoint therapy resistance with novel techniques
El-Serafi et al. Cyclophosphamide alters the gene expression profile in patients treated with high doses prior to stem cell transplantation
WO2014058853A3 (en) Igm therapy in prevention of onset, progression, and recurrence of autoimmune type 1 diabetes
Zhang et al. Sequence-dependent effect of triptolide with gefitinib on the proliferation and apoptosis of lung adenocarcinoma cell H1975
Xie et al. MEK inhibitors potentiate tumor immune surveillance by enhancing cancer cell response of IFNγ
Bensalem Gemcitabine/vinorelbine
Orelli et al. Abstract B23: Preclinical evaluation of a PARP inhibitor in mice representing genetically different subtypes of pancreatic cancers
Jayappa et al. Soluble agonists in the in vivo macroenvironment generate phenotypic de novo resistance to BTK/Bcl-2 targeted therapies in diverse B-cell malignancies
Chesi et al. Abstract IA25: Targeting genetic heterogeneity in multiple myeloma through immune activation.
Chen Docetaxel/doxorubicin